Posted by Michael Wonder on 30 Jul 2025
Nektar Therapeutics receives fast track designation for rezpegaldesleukin for the treatment of severe to very severe alopecia areata
29 July 2025 - Nektar Therapeutics today announced that the US FDA has granted fast track designation for rezpegaldesleukin for the treatment of severe-to-very severe alopecia areata in adults and paediatric patients 12 years of age and older who weigh at least 40 kilograms.
Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body to stimulate proliferation of inhibitory immune cells known as regulatory T cells.
